Zynext Ventures Invests in Illexcor Therapeutics to Innovate Sickle Cell Disease Treatments Zynext Ventures has announced a significant investment in Illexcor Therapeutics to advance innovative oral therapies for sickle cell disease, highlighting their commitment to healthcare advancements.

Zynext Ventures Invests in Illexcor Therapeutics to Innovate Sickle Cell Disease Treatments #USA #Sickle_Cell #Zynext_Ventures #Illexcor #Pennington